Business Context and Reporting Period
This Form 8-K, filed on January 23, 2002, reports E. I. du Pont de Nemours and Company's (DuPont) earnings for the fourth quarter and full year ended December 31, 2001. The company underwent significant restructuring in 2001, including the sale of its Pharmaceuticals business and selected Polyester operations, to address a difficult global economic environment.
Key Financial Metrics
| Metric | Q4 2001 | Q4 2000 | Full Year 2001 | Full Year 2000 |
|---|---|---|---|---|
| Consolidated Sales ($ millions) | 5,229 | 6,316 | 24,726 | 28,268 |
| Segment Sales ($ millions) | 5,931 | 7,174 | 27,689 | 31,677 |
| Net Income ($ millions) | 3,915 | 261 | 4,339 | 2,314 |
| Underlying Net Income ($ millions) | 124 | 494 | 1,251 | 2,878 |
| Diluted EPS (Reported) | $3.82 | $0.25 | $4.16 | $2.19 |
| Diluted EPS (Underlying) | $0.12 | $0.47 | $1.19 | $2.73 |
| Segment ATOI ($ millions) | 4,043 | 459 | 4,936 | 3,094 |
| Underlying Segment ATOI ($ millions) | 252 | 692 | 1,859 | 3,677 |
Debt and Liquidity: The filing text does not provide specific values for total debt, cash flow from operations, or liquidity ratios. However, it notes that restructuring actions are expected to result in lower interest expense and fewer shares outstanding.
Material Changes vs. Prior Period
- Revenue Decline: Consolidated sales decreased 17% in Q4 2001 and 13% for the full year compared to 2000. Excluding divestitures, segment sales dropped 12% in Q4 and 10% for the full year, driven by lower worldwide volumes and selling prices.
- Earnings Volatility: Reported Q4 earnings were inflated by a one-time gain of $3.82 per share from the sale of DuPont Pharmaceuticals. Underlying earnings per share fell 74% in Q4 and 56% for the full year compared to 2000.
- Segment Performance: Underlying After-Tax Operating Income (ATOI) declined across all segments. Notable drops included Nylon (ATOI down 73% in Q4), Specialty Polymers (down 49%), and Polyester (which swung from a profit to a $29 million loss in Q4).
- Cost Factors: Lower energy and raw material costs provided an estimated $120 million after-tax benefit in Q4, partially offsetting the impact of lower volumes and prices.
Guidance, Outlook, and Risks
Outlook: Management expects 2002 underlying earnings per share to exceed 2001 levels despite recessionary pressures. Q1 2002 underlying EPS is expected to be substantially above Q4 2001 but below Q1 2001. The company anticipates global GDP growth averaging just below 1% in 2002, with the second half of the year expected to be stronger than the first.
Management Commentary: CEO Charles O. Holliday Jr. stated that 2001 restructuring and portfolio actions positioned the company with "exceptional financial strength" to deliver competitively superior earnings in the future. He acknowledged "rough water ahead" for manufacturers through the first half of 2002.
Risks and Contingencies:
- Pricing Pressure: Low manufacturing utilization rates may constrain pricing improvements, limiting margin benefits from lower input costs.
- Market Weakness: Continued softness in electronics, high-technology, and apparel markets.
- Legal and Regulatory: Ongoing litigation reserves, including YieldGard corn litigation with Monsanto and Benlate fungicide litigation.
- Macroeconomic Factors: Inflation, interest rates, and foreign currency exchange rates.
Investor Verification Checklist
- Verify the sustainability of the $3.8 billion gain from the sale of DuPont Pharmaceuticals and its impact on reported vs. underlying earnings.
- Confirm the extent of inventory reductions by customers in the Performance Coatings & Polymers and Electronics segments.
- Monitor the progress of the restructuring plan, specifically the realization of fixed cost reductions and the integration of remaining businesses.
- Assess the impact of the global recession on the Nylon and Polyester segments, which showed significant volume and margin declines.
- Review the status of litigation reserves mentioned in the footnotes (YieldGard and Benlate) for potential future charges.